Table of ContentsnnnSection 1 General Strategies for Molecular Targeting in OncologynnChapter 1 The Cell Cycle: Therapeutic Targeting of Cell CyclenRegulatory Components and Effector Pathways in CancernChad D. Knights and Richard G. PestellnChapter 2 mTOR: Properties and TherapeuticsnJohn B. Easton and Peter J. HoughtonnnChapter 3 Ras/Raf/MEK InhibitorsnJoseph A. SparanonnChapter 4 17AAG: Targeting the Molecular Chaperone Heat Shock Protein 90nLen Neckers and Percy IvynChapter 5 The Cancer Epigenome: Can it be targeted for therapy?nSam Thiagalingam and Douglas V. FallernnnSection 2 Molecular Targeting for Specific Disease SitesnnChapter 6 Molecular targeting in upper gastrointestinal malignanciesnScott WadlernnChapter 7 Molecular Targeting of Colorectal Cancer: An Idea Whose TimenHas ComenMark L. Sundermeyer, Alfonso Bellacosa, and Neal J. MeropolnnChapter 8 Molecular Targeting in Hepatocellular CarcinomanJonathan D. Schwartz. and Josep M. LlovetnnChapter 9 Molecularly Targeted Therapy in Pancreatic CancernAnupama Goel and Peter KozuchnnChapter 10 Untargeted Use of Targeted Therapy: A Dilemma in Non-SmallnCell Lung CancernCheryl Ho, Angela M. Davies, Primo N. Lara, O. Gautschi, P.C. Mack,nPaul H. Gumerlock and David R. GandarannChapter 11 Molecular Targeting in Oncology: Renal Cell CancernOlwen Hahn and Walter StadlernnChapter 12 Targeted Therapies for Prostate CancernElisabeth I. Heath and Michael A. CarduccinnChapter 13 Molecular Targets in Ovarian Cancer and Endometrial CancernNilofer S. Azad, Gisele Sarosy, and Elise C. KohnnnChapter 14 Targeted Therapy for Breast CancernDeena M. Atieh and Linda T. VahdatnnChapter 15 MelanomanAkshay Gupta and John M. KirkwoodnnnSection 3 Classes of Drugs for Molecular Targeting in OncologynnChapter 16 Antibody Therapy of CancernHossein Borghaei, Liat Binyamin, Igor Astsaturov, and Louis M. WeinernnChapter 17 Nucleic Acid Therapies for Cancer TreatmentnDan T. Vogl and Alan M. GewirtznnChapter 18 Engineering Oncolytic Measles Viruses for Targeted CancernTherapynTakafumi Nakamura and Stephen J. RussellnnChapter 19 Vaccines as Targeted Cancer TherapynMiguel-Angel Perales, Jedd D. Wolchok and Howard L. KaufmannnChapter 20 Cytokine based therapy for cancernHenry B. Koon and Michael B. AtkinsnnChapter 21 Cyclooxygenase-2 (Cox-2) as a Target for Cancer Preventionnand TreatmentnMonica Bertagnolli, Jaye L. Viner, and Ernest T. HawknnnSection 4 Specific Drugs for Molecular Targeting in OncologynnChapter 22 Imatinib Mesylate (Gleevec) and the emergence ofnchemotherapeutic drug-resistant mutationnGerald V. DenisnnChapter 23 Development of a Targeted Treatment for Cancer: The Examplenof C225 (Cetuximab)nJohn MendelsohnnnChapter 24 VEGF Inhibition for Cancer TherapynShermini Saini and Herbert HurwitznnChapter 25 Somatostatin analogue therapynManish C. Champaneria, M.D., Irvin M. Modlin, M.D., Ph.D., D.Sc., IgornLatich, M.D., Jan Bornschein, Ignat Drozdov, Mark Kidd, Ph.D.nnnnSection 5 Challenges in Molecular Targeting in OncologynnChapter 26 Patient Selection for Rational Development of NovelnAnticancer AgentsnGrace K. Dy and Alex A. AdjeinnChapter 27 Clinical Trial Design with Targeted AgentsnSarita Dubey and Joan H. SchillernnChapter 28 How to define treatment success or failure if tumors don'tnshrink: Consequences for trial design.nJJEM Kitzen, MJA de Jonge, and J VerweijnnChapter 29 Molecular Imaging in OncologynLalitha Shankar, Anne Menkens, and Daniel C. SullivannnChapter 30 Combinations of Molecular Targeted Therapies - Opportunitiesnand ChallengesnHelen X. Chen and Janet E. DanceynnChapter 31 Preclinical Development of Molecularly Targeted Agents
This book presents an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer. It is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice.
Molecular Targeting in Oncology covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way that readers may begin with chapters that most interest them and work through the rest in the order of their choice. The book is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second describes how clinicians are evaluating targeted therapies in specific organ systems. The third illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more.